A paper in the PLOS Biology journal questions the mechanism of PTC Therapeutics' (PTCT) Ataluren...

|About: PTC Therapeutics (PTCT)|By:, SA News Editor

A paper in the PLOS Biology journal questions the mechanism of PTC Therapeutics' (PTCT) Ataluren (PTC124) drug, which is designed to restore the genetic production of a functional protein and potentially treat genetic diseases. Researchers found "no evidence of activity for PTC124" across a "diverse range of in vitro reporter assays." The paper comes just six days after PTC Therapeutics carried out an upsized IPO at $15 a share.